When it comes to medical cannabis, Israel has long been among the leading nations in the world. You can read a post I wrote about Israel’s achievements on that front, both in terms of legality and actual research, here. But despite its deep history with medical cannabis, the country still does not permit legal sales
Big news from the Oregon Liquor and Cannabis Commission (OLCC) this week as it announced it has resumed accepting and processing of new marijuana retailer, wholesaler, and processor applications submitted after June 15, 2018. This is welcome news as the OLCC had imposed an administrative “pause” on new applications to focus on existing licensees and
Something strange happened yesterday. Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “breathtaking” in the words of Compass’ CEO. Immediately, the company’s publicly traded shares dropped 16%. Including the day prior, it
As we have written about before, the corporate practice of medicine doctrine (“CPOM”) is a creature of state law (click here to review a prior post on CPOM). While some states do not have a CPOM doctrine (like Florida), other states have very strict CPOM doctrines (like New York and California). At its core, CPOM
Legal representation in disputes with insurers has become paramount for cannabis companies in an ever-expanding operational environment. Cannabis companies may seek to insure against risk of loss as a result of challenges such as unexpected fires, crop protection, business interruption, or adverse consumer reactions to products. In many instances, cannabis companies are even required to
Since California passed the Compassionate Use Act in 1996, there have always been folks who insist that federal legalization is right around that corner. As more and more states decriminalized and then regulated cannabis, the ranks of people who believe federal legalization is imminent has grown exponentially. Recently, when Joe Biden won the presidency, it
Public and scientific interest in psychedelics such as psilocybin and MDMA is expanding. Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Psilocybin, a
You are an experienced cannabis operator. You have dealt with nonsensical regulations. You’ve navigated the world of dealing with a highly regulated substance. You’ve solicited large investments and beat out your competitors. You’ve learned enough about corporate governance and tax to go toe to toe with the best. Think you can easily pivot to the
New York’s Cannabis Control Board (CCB) held its third meeting yesterday, November 3, 2021. As will be the case with all CCB meetings, it was broadcast live and a transcript of the meeting will be published here. We were pretty clear with what we were hoping for coming out of the CCB’s third meeting and
I often write about various discrete aspects of cannabis M&A transactions. A full list of my posts, along with other Canna Law Blog contributors’ posts, is linked at the bottom of this post. Today, rather than looking at individual elements of a cannabis M&A transaction, I want to walk through what a transaction looks like
